{"title":"恶性胸膜间皮瘤的治疗进展","authors":"Zhu Jie","doi":"10.31435/rsglobal_ws/30092022/7854","DOIUrl":null,"url":null,"abstract":"Malignant pleural mesothelioma (MPM) is a rare primary tumor originating from pleural mesothelial cells with insidious onset, high invasiveness and malignancy. Early symptoms are not obvious, lack of specific symptoms, and the diagnosis is difficult, and it depends on the pathological tissue for immunohistochemistry to confirm the diagnosis. Only a small number of patients can receive radical surgery, and the current treatment method is chemotherapy. This article reviews the diagnosis, treatment and progress of MPM diagnosis and treatment status.","PeriodicalId":19855,"journal":{"name":"Pharmacy World & Science","volume":"56 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"ADVANCES IN THE TREATMENT OF MALIGNANT PLEURAL MESOTHELIOMA\",\"authors\":\"Zhu Jie\",\"doi\":\"10.31435/rsglobal_ws/30092022/7854\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Malignant pleural mesothelioma (MPM) is a rare primary tumor originating from pleural mesothelial cells with insidious onset, high invasiveness and malignancy. Early symptoms are not obvious, lack of specific symptoms, and the diagnosis is difficult, and it depends on the pathological tissue for immunohistochemistry to confirm the diagnosis. Only a small number of patients can receive radical surgery, and the current treatment method is chemotherapy. This article reviews the diagnosis, treatment and progress of MPM diagnosis and treatment status.\",\"PeriodicalId\":19855,\"journal\":{\"name\":\"Pharmacy World & Science\",\"volume\":\"56 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-09-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmacy World & Science\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.31435/rsglobal_ws/30092022/7854\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacy World & Science","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31435/rsglobal_ws/30092022/7854","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
ADVANCES IN THE TREATMENT OF MALIGNANT PLEURAL MESOTHELIOMA
Malignant pleural mesothelioma (MPM) is a rare primary tumor originating from pleural mesothelial cells with insidious onset, high invasiveness and malignancy. Early symptoms are not obvious, lack of specific symptoms, and the diagnosis is difficult, and it depends on the pathological tissue for immunohistochemistry to confirm the diagnosis. Only a small number of patients can receive radical surgery, and the current treatment method is chemotherapy. This article reviews the diagnosis, treatment and progress of MPM diagnosis and treatment status.